Wird geladen...

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy

BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib can provide better efficacy and prolonged progression free survival (PFS) than cytotoxic chemotherapy for metastatic lung non-squamous cell carcinoma harboring susceptible EGFR mutations when used a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Pharmacol Toxicol
Hauptverfasser: Yang, Chih-Jen, Hung, Jen-Yu, Tsai, Ming-Ju, Wu, Kuan-Li, Liu, Ta-Chih, Chou, Shah-Hwa, Lee, Jui-Ying, Hsu, Jui-Sheng, Huang, Ming-Shyan, Chong, Inn-Wen
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2017
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5424380/
https://ncbi.nlm.nih.gov/pubmed/28486985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-017-0130-0
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!